Corcept Therapeutics (CORT) Shares Outstanding (Weighted Average) (2010 - 2026)

Corcept Therapeutics has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $104.4 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $104.4 million, changed 0.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $104.4 million (changed 0.32% YoY), and the FY2025 annual result was $103.9 million, up 0.61% from the prior year.
• Shares Outstanding (Weighted Average) came in at $104.4 million for Q1 2026 at Corcept Therapeutics, up from $103.9 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $107.9 million in Q1 2023 to a low of $102.0 million in Q3 2023.
• The 5-year median for Shares Outstanding (Weighted Average) is $104.1 million (2025), against an average of $104.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) declined 9.25% in 2022 and gained 1.77% in 2023, its largest moves.
• Corcept Therapeutics' Shares Outstanding (Weighted Average) stood at $106.8 million in 2022, then declined by 3.02% to $103.6 million in 2023, then slipped by 0.32% to $103.2 million in 2024, then advanced by 0.61% to $103.9 million in 2025, then gained by 0.55% to $104.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $104.4 million (Q1 2026), $103.9 million (Q4 2025), and $103.9 million (Q3 2025), per Business Quant data.